Michael Newman - Indaptus Therapeutics Chief Founder
| INDP Stock | USD 7.30 0.86 10.54% |
Insider
Michael Newman is Chief Founder of Indaptus Therapeutics
| Age | 69 |
| Address | Three Columbus Circle, New York, NY, United States, 10019 |
| Phone | 646 427 2727 |
| Web | https://indaptusrx.com |
Michael Newman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Newman against Indaptus Therapeutics stock is an integral part of due diligence when investing in Indaptus Therapeutics. Michael Newman insider activity provides valuable insight into whether Indaptus Therapeutics is net buyers or sellers over its current business cycle. Note, Indaptus Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Indaptus Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Newman over six months ago Discretionary transaction by Michael Newman of tradable shares of Indaptus Therapeutics subject to Rule 16b-3 | ||
Michael Newman over six months ago Acquisition by Michael Newman of 290000 shares of Indaptus Therapeutics at 8.87 subject to Rule 16b-3 |
Indaptus Therapeutics Management Efficiency
The company has return on total asset (ROA) of (1.2221) % which means that it has lost $1.2221 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.59) %, meaning that it created substantial loss on money invested by shareholders. Indaptus Therapeutics' management efficiency ratios could be used to measure how well Indaptus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 08/04/2025, Return On Tangible Assets is likely to drop to -2.15. In addition to that, Return On Capital Employed is likely to grow to -3.7. As of 08/04/2025, Total Current Liabilities is likely to drop to about 3.4 M. In addition to that, Liabilities And Stockholders Equity is likely to drop to about 7 MSimilar Executives
| Found 11 records | INSIDER Age | ||
| James Ahlers | RenovoRx | 60 | |
| Ramtin MD | RenovoRx | 59 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 56 | |
| Ronald CPA | RenovoRx | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 63 | |
| Tiago Marques | Pasithea Therapeutics Corp | 47 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 61 | |
| MD BA | Pasithea Therapeutics Corp | 76 | |
| Angela Nelms | RenovoRx | 47 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 41 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 47 | |
Management Performance
| Return On Equity | -2.59 | ||||
| Return On Asset | -1.22 |
Indaptus Therapeutics Leadership Team
Elected by the shareholders, the Indaptus Therapeutics' board of directors comprises two types of representatives: Indaptus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Indaptus. The board's role is to monitor Indaptus Therapeutics' management team and ensure that shareholders' interests are well served. Indaptus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Indaptus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Chief Officer | ||
| Jeffrey JD, CEO Director | ||
| Jeffrey Meckler, CEO Director | ||
| Nir Sassi, Secretary CFO | ||
| Walt Esq, Chief Officer | ||
| Michael Newman, Chief Founder | ||
| Boyan MD, Chief Officer |
Indaptus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Indaptus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.59 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 348.89 K | ||||
| Shares Outstanding | 572.66 K | ||||
| Shares Owned By Insiders | 19.42 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 14.72 K | ||||
| Price To Book | 1.49 X | ||||
| EBITDA | (15.02 M) | ||||
| Net Income | (15.02 M) |
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.